CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 92 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Epcoritamab July 24, 2026 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... September 24, 2024 Load more HOT NEWS Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria Even If Insured, People with Advanced Cancer Often Face Financial Problems Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical...
